Literature DB >> 9772210

Location of aluminium and gallium in human neuroblastoma cells treated with metal-chelating agent complexes.

C B Dobson1, J P Day, S J King, R F Itzhaki.   

Abstract

The subcellular location of aluminium is unknown, probably because of difficulties in investigating aluminium biochemistry and the use of varied experimental approaches of uncertain sensitivity. We have studied levels of uptake and the localization of gallium and of aluminium in cultured human neuroblastoma cells treated with soluble metal complexes (mainly Al- or Ga-EDTA), radiolabeled with 26Al or 67Ga, respectively. Crude nuclei and cytoplasm were obtained by two separate methods, and DNA, RNA, and proteins were prepared from the nuclei by centrifugation in high salt; also, cytosol and noncytosol were separated using a nondissociating method. Levels of uptake were of similar order for the two metals-on average about 50 pmol/10(6) cells for aluminium and 120 pmol/10(6) cells for gallium, after 4 to 8 days treatment at 250 microM, and approximately 50 to 70% of the metal was found in the cytosol. About 20% of the aluminium and 10 to 25% of the gallium was associated with nuclear protein. A lower proportion was bound to DNA and to nuclear RNA. In cells treated with gallium-citrate/transferrin mixtures, 30 to 35% of the gallium in the cytosol was bound to protein, at least 35 being loosely bound; the main gallium-associated protein was probably intracellular transferrin. The remaining 65 to 70% of the metal in the cytosol was in low-molecular-weight form, and we suggest that the latter metal could affect structures such as the cytoskeleton and also metabolic processes in the cytoplasm. The similarity in distribution of the two metals supports the use of gallium as a "surrogate" for aluminium, at least in cell culture studies. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9772210     DOI: 10.1006/taap.1998.8489

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  2 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

2.  Beraprost sodium protects against chronic brain injury in aluminum-overload rats.

Authors:  Yongquan Pan; Lijuan Yu; Wenjuan Lei; Yuanxin Guo; Jianfeng Wang; Huarong Yu; Yong Tang; Junqing Yang
Journal:  Behav Brain Funct       Date:  2015-02-07       Impact factor: 3.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.